Product Description
Mechanisms of Action:
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Hoffmann-La Roche
Company Location:
Company CEO: Severin Schwan
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Type 2 Diabetes
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00057304 |
BM17151 | P2 |
Completed |
Type 2 Diabetes |
2004-03-01 |
2023-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments |
Recent News Events
Date |
Type |
Title |
|---|